The Europe Glycated Albumin Assay Market should witness market growth of 7.9% CAGR during the forecast period (2023-2030).
Glycemic regulation is necessary for diabetes treatment. Numerous estimations provide pointers, including glycated hemoglobin (HbA1c), 1, 5-anhydroglucitol (1,5AG), and glycated albumin. The glycemic level during the first three months of diabetes frequency is shown by glycated hemoglobin (HbA1c). For the confirmation of temporary restorative viability, while starting diabetes treatment, this test is essential.
In the near future, the market is expected to experience rapid expansion and improvements. The importance of glycated albumin testing in clinical practice is anticipated to rise due to the rising prevalence of diabetes and the requirement for efficient glycemic control monitoring. This assay has several benefits compared to conventional glycated hemoglobin (HbA1c) testing, including quicker turnaround times, sensitivity to recent glycemic alterations, and independence from variables like erythrocyte durability and specific hemoglobin variations.
Nearly one in seven UK residents are expected to be over the age of 75 by 2040, according to a government assessment titled “Future of an aging population” (UK). There will be 1.42 million more homes with a head of household who is 85 years of age or older by 2037, a rise of 161% over the previous 25 years. Over 5.5 million more people will be added to the working-age population between the ages of 50 and the state pension age (SPA), from 26% in 2012 to 34% in 2050. According to a UN assessment of France aging policy, France, like other European nations, is experiencing a steady and large rise in the population of senior people. In 2012, there were 15 million persons in France over the age of 60. In 2060, this number will increase to 24 million. It is anticipated that the market will grow as a result of the aging population in these regional nations which raise the risk of diabetes.
The Germany market dominated the Europe Glycated Albumin Assay Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $24,356.5 Thousands by 2030. The UK market is exhibiting a CAGR of 7% during (2023-2030). Additionally, The France market would experience a CAGR of 8.7% during (2023-2030).
Based on Application, the market is segmented into Type 2 Diabetes, Type 1 Diabetes, and Prediabetes. Based on End-user, the market is segmented into Hospitals & Diabetic Care Center, Diagnostic Laboratory, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Asahi Kasei Pharma Corporation(Asahi Kasei Corporation), EKF Diagnostics Holdings plc, Weldon Biotech India Private Limited, Hzymes Biotechnology Co., Ltd., Beijing Strong Biotechnologies, Inc., Diazyme Laboratories, Inc. (General Atomics), Abbexa Limited, Biomatik Corporation, Abnova Corporation and Geno Technology, Inc.
Glycemic regulation is necessary for diabetes treatment. Numerous estimations provide pointers, including glycated hemoglobin (HbA1c), 1, 5-anhydroglucitol (1,5AG), and glycated albumin. The glycemic level during the first three months of diabetes frequency is shown by glycated hemoglobin (HbA1c). For the confirmation of temporary restorative viability, while starting diabetes treatment, this test is essential.
In the near future, the market is expected to experience rapid expansion and improvements. The importance of glycated albumin testing in clinical practice is anticipated to rise due to the rising prevalence of diabetes and the requirement for efficient glycemic control monitoring. This assay has several benefits compared to conventional glycated hemoglobin (HbA1c) testing, including quicker turnaround times, sensitivity to recent glycemic alterations, and independence from variables like erythrocyte durability and specific hemoglobin variations.
Nearly one in seven UK residents are expected to be over the age of 75 by 2040, according to a government assessment titled “Future of an aging population” (UK). There will be 1.42 million more homes with a head of household who is 85 years of age or older by 2037, a rise of 161% over the previous 25 years. Over 5.5 million more people will be added to the working-age population between the ages of 50 and the state pension age (SPA), from 26% in 2012 to 34% in 2050. According to a UN assessment of France aging policy, France, like other European nations, is experiencing a steady and large rise in the population of senior people. In 2012, there were 15 million persons in France over the age of 60. In 2060, this number will increase to 24 million. It is anticipated that the market will grow as a result of the aging population in these regional nations which raise the risk of diabetes.
The Germany market dominated the Europe Glycated Albumin Assay Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $24,356.5 Thousands by 2030. The UK market is exhibiting a CAGR of 7% during (2023-2030). Additionally, The France market would experience a CAGR of 8.7% during (2023-2030).
Based on Application, the market is segmented into Type 2 Diabetes, Type 1 Diabetes, and Prediabetes. Based on End-user, the market is segmented into Hospitals & Diabetic Care Center, Diagnostic Laboratory, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Asahi Kasei Pharma Corporation(Asahi Kasei Corporation), EKF Diagnostics Holdings plc, Weldon Biotech India Private Limited, Hzymes Biotechnology Co., Ltd., Beijing Strong Biotechnologies, Inc., Diazyme Laboratories, Inc. (General Atomics), Abbexa Limited, Biomatik Corporation, Abnova Corporation and Geno Technology, Inc.
Scope of the Study
By Application
- Type 2 Diabetes
- Type 1 Diabetes
- Prediabetes
By End-user
- Hospitals & Diabetic Care Center
- Diagnostic Laboratory
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Asahi Kasei Pharma Corporation(Asahi Kasei Corporation)
- EKF Diagnostics Holdings plc
- Weldon Biotech India Private Limited
- Hzymes Biotechnology Co., Ltd.
- Beijing Strong Biotechnologies, Inc.
- Diazyme Laboratories, Inc. (General Atomics)
- Abbexa Limited
- Biomatik Corporation
- Abnova Corporation
- Geno Technology, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Europe Glycated Albumin Assay Market by Application
Chapter 5. Europe Glycated Albumin Assay Market by End User
Chapter 6. Europe Glycated Albumin Assay Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Asahi Kasei Pharma Corporation (Asahi Kasei Corporation)
- EKF Diagnostics Holdings plc
- Weldon Biotech India Private Limited
- Hzymes Biotechnology Co., Ltd.
- Beijing Strong Biotechnologies, Inc.
- Diazyme Laboratories, Inc. (General Atomics)
- Abbexa Limited
- Biomatik Corporation
- Abnova Corporation
- Geno Technology, Inc.
Methodology
LOADING...
